Restorbio
As of the edition of 20 October 2026, Restorbio runs 1 drug; it is on route A at 5 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Restorbio was renamed.
- Restorbio Inc.: renamed
Drugs by status
| Status | Count |
|---|---|
| Went quiet | 1 |
| Total | 1 |
Where it needs a new molecule
Route A at 5 targets, route B at 0 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Restorbio needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 5 trials led
- Lungs and airways: 5 trials led
- Inherited and neonatal: 3 trials led